论文部分内容阅读
他曾为医药事业的发展倾注了,他奋斗在新药研究开发和科技管理工作的征程中。上世纪90年代中期,李光平由上海市科委委派,担任中方谈判代表负责国家科委推荐和上海市积极引进的生物医药合资项目的谈判,负责(中日合资)麒麟鲲鹏(中国)生物药业有限公司筹建工作。 麒麟鲲鹏(中国)生物药业有限公司是国家科技部推荐,上海市政府积极引进的高科技生物医药项目,是日本著名大型企业麒麟啤酒株式会社在海外投资的最大医药项目。中方合作伙伴是在国内具有影响的上海新药研究开发中心、张江
He devoted himself to the development of the pharmaceutical industry and he worked hard on the journey of research, development and technology management of new drugs. In the mid 90s of last century, Li Guangping was appointed by the Shanghai Municipal Science and Technology Commission as the negotiator for the Chinese side in charge of negotiations between the State Science and Technology Commission and the Shanghai Municipality on the active introduction of biomedical joint venture projects. He was responsible for the (Sino-Japanese joint venture) Kirin (China) Biopharmaceutical Industry Co., Ltd. preparation work. Kirin Kunpeng (China) Bio-Pharmaceutical Co., Ltd. is recommended by the Ministry of Science and Technology, the Shanghai municipal government to actively introduce high-tech biomedical projects, is the famous Japanese large-scale Kirin Brewery Co., Ltd. overseas investment in the largest pharmaceutical project. The Chinese partner is Zhang Jiang, Shanghai New Drug Research and Development Center that has an influence in China